Navigation Links
New Immune Approach for Treatment of Alzheimer's Disease
Date:6/8/2009

New hope for a much needed new approach for tackling Alzheimer's disease will be discussed in detail this week at a new medical conference in Philadelphia. At the inaugural Targeting Alzheimer's with Novel Therapeutics conference, to be held as part of the 8th annual World Pharmaceutical Congress, Edward Tobinick MD, Director of the Institute for Neurological Research, a private medical group, inc. in Los Angeles, will present the latest data on a revolutionary new immune approach for treatment of Alzheimer's disease.

Los Angeles, CA (PRWEB) June 8, 2009 -- New hope for a much needed new approach for tackling Alzheimer's disease will be discussed in detail this week at the inaugural Targeting Alzheimer's with Novel Therapeutics conference, to be held as part of the 8th annual World Pharmaceutical Congress in Philadelphia on June 10 and 11. On the second day of this conference, after presentations by researchers from Abbott Laboratories, Medivation, Epix Pharmaceuticals, the Buck Institute, Cleveland Clinic, and others, Edward Tobinick MD, Director of the Institute for Neurological Research® (INR®), a private medical group, inc. in Los Angeles, will present the latest data on a revolutionary new immune approach for treatment of Alzheimer's disease.

Dr. Tobinick's presentation, entitled TNF modulation for treatment of Alzheimer's Disease, will review the remarkable results which have been documented using perispinal administration of etanercept, a therapeutic developed through recombinant DNA biotechnology, for treatment of Alzheimer's disease (1-7). This patented (8) off-label treatment method, invented and developed at the INR, may produce clinical improvement within minutes (1-6).

Localized administration of etanercept for treatment of neurological disorders is a novel concept which was invented by Dr. Tobinick a decade ago (8). The proof-of-concept of these novel methods which Dr. Tobinick invented (8, 9), which include both perispinal and epidural etanercept for treatment of sciatica (see INR sciatica website) (8), are now supported by additional, independent studies from academic centers, including a new randomized, double-blind, placebo-controlled clinical trial from Johns Hopkins and Walter Reed Army Medical Center (10, 11).

The prospect of a new, immune-based approach for treatment of Alzheimer's is exciting. Recent reports of the ability of etanercept to penetrate rapidly into the cerebrospinal fluid within the brain in animal studies now provide new insight into the potential mechanisms underlying the rapid clinical effects of etanercept in patients with Alzheimer's disease (12). Patient treatment is currently available at the Institute in Los Angeles, and at the Institute's new office in Newport Beach, California. Further information is available on the website of the INR, at Institute for Neurological Research in Los Angeles website.

References

1. Tobinick, E., Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today, 2009. 14(3-4): p. 168-77.
2. Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol, 2008. 8: p. 27.
3. Tobinick, E.L. and H. Gross, Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation, 2008. 5: p. 2.
4. Griffin, W.S., Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation, 2008. 5: p. 3.
5. Tobinick, E., Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res, 2007. 4(5): p. 550-2.
6. Tobinick, E., H. Gross, A. Weinberger, and H. Cohen, TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed, 2006. 8(2): p. 25.
7. McAlpine, F.E. and M.G. Tansey, Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's. J Inflammation Research, 2008. 1: p. 29-39.
8. U.S. patents 6,015,557; 6,177,077; 6,419,944; 6,537,549; 6,982,089; 7,214,658, and Australian patent 758,523 issued to Edward Tobinick MD and assigned to TACT IP, LLC, and additional patents and related applications, assigned to TACT IP, LLC.
9. Tobinick, E. and S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85.
10. Cohen, S.P., N. Bogduk, A. Dragovich, C.C. Buckenmaier, 3rd, S. Griffith, C. Kurihara, J. Raymond, P.J. Richter, N. Williams, and T.L. Yaksh, Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology, 2009. 110(5): p. 1116-26.
11. Kato, K., S. Kikuchi, V.I. Shubayev, and R.R. Myers, Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience, 2009. 160(2): p. 492-500.
12. Tobinick, E.L., K. Chen, and X. Chen, Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes, 2009. 2: p. 28.

# # #

Read the full story at http://www.prweb.com/releases/etanercept/alzheimers/prweb2507234.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. Immune deficiency linked to a type of eye cancer
3. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
4. Melanoma drug revs immune cells but cancer cells ignore it
5. Study identifies key player in the bodys immune response to chronic stress
6. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
7. UVA researchers find important clue to immune infertility
8. M.D. Anderson-led team reports possible key to autoimmune disease
9. Their immune cells, fighting your cancer
10. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
11. Occupational exposures may be linked to death from autoimmune disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
Breaking Medicine Technology: